# Bioelectronic Medicine **Entity class:** Discipline **Domain:** Peripheral Neuromodulation / Organ Regulation **Doc Type:** Discipline Node **Maturity:** Commercial **Collection:** [[collections/Neurotech|Neurotech]] **Primary Sources:** [[research/Research Inferences|Research Inferences]] (INF-0066, INF-0306) ## Definition **Bioelectronic medicine treats organ function as a control problem addressed through nerves, using electrical stimulation to set physiological parameters that would otherwise be set by drugs.** Its founding demonstration is the inflammatory reflex: stimulating the vagus nerve modulates systemic inflammatory signaling through a defined neural circuit, which means an electrical device can set an immunological parameter. The field's name and much of its early work come from the Feinstein Institutes, where Kevin Tracey characterized that reflex. ## Clinical record - **Rheumatoid arthritis (30 July 2025).** The FDA approved SetPoint Medical's implanted system, the first neuroimmune modulation therapy for the indication, for adults with moderate-to-severe disease who do not respond to or cannot tolerate biologic or targeted synthetic DMARDs. The device delivers a low-voltage signal for 60 seconds a day from a neurostimulator below the left clavicle. Approval rested on RESET-RA, a randomized sham-controlled trial of 242 patients; public summaries report ACR20 at three months of 35.2% against 24.2% for sham. - **Epilepsy and depression.** Implanted cervical [[wiki/Vagus Nerve Stimulation|vagus nerve stimulation]] has carried FDA approvals since 1997 and 2005. - **Stroke rehabilitation (2021).** Paired stimulation and motor therapy for upper-limb recovery. - **Wearable routes.** A *Med-X* review of 25 August 2026 covers auricular and cervical wearable stimulation for treatment-resistant depression with AI-driven closed-loop personalization. ## Forward Capability A stimulation parameter can be changed instantly and recalled; a pharmaceutical dose cannot. That control-theoretic advantage moves indications from drugs to devices wherever a nerve carries the signal, and it makes the peripheral nervous system the first place where continuous closed-loop control of internal state becomes routine. Central interfaces will inherit a control theory developed peripherally, and an implanted controller with read and write access to autonomic traffic turns homeostatic setpoints into adjustable parameters. ## Open Questions - Peer-reviewed RESET-RA results in full. - Which further immune and metabolic indications follow the arthritis precedent. - Where the off switch lives in a device that regulates physiology continuously, and who holds it. ## Research Inferences These entries translate the forward-looking register in [[research/Research Inferences|Research Inferences]] into ordinary wiki prose. The tier labels apply to the inference, not automatically to every factual anchor inside it. Proposed IDs above INF-0500 come from the 2026-10-23 cycle: [[research/Research Inferences Integration Report - 2026-10-23|Research Inferences Integration Report — 2026-10-23]] · [[research/Research Inferences Integration Audit - 2026-10-23|Research Inferences Integration Audit — 2026-10-23]]. - **INF-0047 — Strongly indicated.** The peripheral nervous system is accessible without craniotomy and carries organ-regulatory traffic, which makes it the first place where continuous closed-loop control of the body's internal state becomes routine. Central interfaces will inherit a control theory developed peripherally. - **INF-0066 — Plausible.** Electrical modulation of autonomic pathways lets a device set inflammatory, metabolic, and cardiac setpoints continuously. That is real-time regulation of body systems by an implanted controller, and it arrives under ordinary disease indications rather than as enhancement. - **INF-0305 — Established.** Stimulating the vagus modulates systemic inflammatory signaling through a defined neural reflex, which means an electrical device can set an immunological parameter. Electricity substituting for a drug is the founding demonstration of bioelectronic medicine, and its indications expand annually. - **INF-0306 — Strongly indicated.** A stimulation parameter can be changed instantly and reversibly, while a pharmaceutical dose cannot be recalled once administered. Reversibility gives electrical therapeutics a control-theoretic advantage that will move indications from drugs to devices wherever a nerve carries the signal. - **INF-0307 — Plausible.** If an implanted controller can read and write autonomic traffic, homeostatic setpoints become adjustable parameters rather than fixed biology. Adjustable setpoints are the mechanism by which medicine crosses from treatment into specification of the body's operating conditions. ## Relationships - **founding_mechanism:** the inflammatory reflex, via [[wiki/Vagus Nerve Stimulation|Vagus Nerve Stimulation]]. - **institutional_lineage:** Kevin Tracey and the Feinstein Institutes, whose BCI work in the corpus runs through [[wiki/Double Neural Bypass|Double Neural Bypass]] and [[wiki/Chad Bouton|Chad Bouton]]. - **cluster_home:** [[wiki/In-Body Regulation and Autonomous Physiology|In-Body Regulation and Autonomous Physiology]] · [[wiki/Networked Body|Networked Body]] · [[wiki/Distributed Biological Interfaces|Distributed Biological Interfaces]]. - **device_peers:** [[wiki/BrainSense Adaptive DBS|BrainSense Adaptive DBS]] (central closed loop) · [[wiki/Motif Neurotech|Motif Neurotech]] (cranial depression stimulator). - **control_class:** [[wiki/Closed-Loop Neuromodulation|Closed-Loop Neuromodulation]] · [[wiki/Closed-Loop Control|Closed-Loop Control]]. - **reviewed_in:** [[wiki/Med-X|Med-X]] (wearable VNS for depression, 25 August 2026). - **ecosystem:** [[wiki/Neurotechnology Ecosystem|Neurotechnology Ecosystem]] · [[collections/Neurotech|Neurotech]]. ## Sources - [FDA approval of the SetPoint System: the first neuroimmune modulation therapy for rheumatoid arthritis — PMC, 2025](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12889326/) - [FDA approves vagus nerve stimulator for rheumatoid arthritis — Healio, 12 September 2025](https://www.healio.com/news/rheumatology/20250912/fda-approves-vagus-nerve-stimulator-for-rheumatoid-arthritis) - [Wearable vagus nerve stimulation for depression — Med-X, 25 August 2026](https://link.springer.com/article/10.1007/s44258-026-00092-8) As of 23 October 2026.